Evidence map›Paper›PMID 33103934›Full record

ReviewExpert review of clinical immunology2020

Gut microbiota in Celiac Disease: microbes, metabolites, pathways and therapeutics.

Katherine L Olshan, Maureen M Leonard, Gloria Serena, Ali R Zomorrodi, Alessio Fasano

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Bacteria: Potential Make-or-Break Determinants of Celiac Disease.International journal of molecular sciences · 2024
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Katherine L OlshanDivision of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, Harvard Medical School , Boston, MA, USA.
Maureen M LeonardDivision of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, Harvard Medical School , Boston, MA, USA.
Gloria SerenaDivision of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, Harvard Medical School , Boston, MA, USA.
Ali R ZomorrodiDivision of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, Harvard Medical School , Boston, MA, USA.
Alessio FasanoDivision of Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for Children, Harvard Medical School , Boston, MA, USA.
Massachusetts General Hospital · USEuropean Biomedical Research Institute of Salerno · ITHarvard University · US

Funding

Microbiome-derived Metabolites Linked to Celiac Disease Onset in Infants at RiskR01DK104344 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FASANO, ALESSIO · 2016 to 2020
$3.4M
Prospective Multi-Omic Analysis of At-Risk infants to Model Celiac Disease PathogenesisK23DK122127 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI LEONARD, MAUREEN MICHELLE · 2019 to 2023
$1.2M
NIDDK NIH HHS K23 DK122127NIDDK NIH HHS R01 DK104344
6 · The paper itself

Abstract

introductionCurrent evidence supports a vital role of the microbiota on health outcomes, with alterations in an otherwise healthy balance linked to chronic medical conditions like celiac disease (CD). Recent advances in microbiome analysis allow for unparalleled profiling of the microbes and metabolites. With the growing volume of data available, trends are emerging that support a role for the gut microbiota in CD pathogenesis. AREAS COVERED: In this article, the authors review the relationship between factors such as genes and antibiotic exposure on CD onset and the intestinal microbiota. The authors also review other microbiota within the human body (like the oropharynx) that may play a role in CD pathogenesis. Finally, the authors discuss implications for disease modification and the ultimate goal of prevention. The authors reviewed literature from PubMed, EMBASE, and Web of Science. EXPERT OPINION: CD serves as a unique opportunity to explore the role of the intestinal microbiota on the development of chronic autoimmune disease. While research to date provides a solid foundation, most studies have been case-control and thus do not have capacity to explore the mechanistic role of the microbiota in CD onset. Further longitudinal studies and integrated multi-omics are necessary for investigating CD pathogenesis.

Indexed as

AnimalsAnti-Bacterial AgentsCeliac DiseaseDysbiosisGastrointestinal MicrobiomeGene-Environment InteractionHost Microbial InteractionsHumansSignal TransductionAnti-Bacterial AgentsCeliac diseasedysbiosisglutengutmicrobiomemicrobiota

Identifiers

PMID33103934
PMCPMC7796936
OpenAlexW3093935905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.